Upifitamab rilsodotin not checked

Mersana Therapeutics · XMT-1536 Antibody Drug Conjugate · XMT-1536

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
5 in total
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study. For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential…”In the company’s words, NCT03319628 on ClinicalTrials.gov
Tested for
Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
Main trialPhase 1/2
“First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) were enrolled in the expansion segment of this study. Patients with platinum-resistant, high-grade serous ovarian cancer were enrolled in the UPLIFT segment of this study. In addition to safety assessments, the pharmacokinetics of the…”In the company’s words, NCT03319628 on ClinicalTrials.gov
Other names
Upifitimab rilsodotin · XMT-1536 Antibody Drug Conjugate · XMT-1536 · UpRi

Other drugs for Platinum Resistant Ovarian Cancer

All 265 drugs for Platinum Resistant Ovarian Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting 31 May 2023 First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Phase 3Terminated 29 Sep 2023 Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
Phase 1Completed 9 Jul 2021 First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b
Phase 1Completed 31 May 2022 First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b
Phase 1Terminated 3 Oct 2023 Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Upifitamab rilsodotin

Following is part of Solo: you see every change to Upifitamab rilsodotin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in